Stock_Titan Posted - 2 days ago

$MRUS Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC https://www.stocktitan.net/news/MRUS/merus-announces-first-patient-dosed-in-li-ge-r-hn2-a-phase-3-trial-75xn2g612phx.html

Biotechnexus Posted - 2 weeks ago

$MRUS will see ATH soon

justiceforb_85 Posted - 2 weeks ago

$IMMP $HOOK $PDSB $MRUS . Great entry if interested in head/neck cancer space.

Stock_Titan Posted - 2 weeks ago

$MRUS Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC https://www.stocktitan.net/news/MRUS/merus-announces-first-patient-dosed-in-phase-2-trial-of-petosemtamab-2yuo0gswmo41.html

intratio Posted - 4 weeks ago

Our machine learning model is forecasting that this stock s value will shortly go down and will continue to trend quite negatively in the next months $MRUS

phatsuit Posted - 4 weeks ago

$MRUS oh yes

justiceforb_85 Posted - 4 weeks ago

@bmess true, the emerging players in this space appear to be $HOOK, $PDSB, and $MRUS. $MRUS had impressive data and is closer to FDA approval with a PDUFA target later this year. But it's hard to compare with phase 2 when these aren't head-to-head. But the head/neck cancer space has enough room for all these players.

Thestocktraderhubzee Posted - 1 month ago

JUN 27 2024. $AAPL B of A Securities Maintains Buy on Apple, Maintains $230 Price Target $RS B of A Securities Maintains Neutral on Reliance, Lowers Price Target to $335 $MRUS Citigroup Maintains Buy on Merus, Raises Price Target to $93 $CLF Citigroup Maintains Buy on Merus, Raises Price Target to $93 $OTEX Citigroup Maintains Neutral on Open Text, Lowers Price Target to $32

intratio Posted - 1 month ago

https://www.intratio.com/stock-forecast/MRUS Merus N.V. Our predictive algorithm reaches the conclusion this company s stock price has a poor setup for the immediate future with a pessimistic long-term perspective $MRUS

AnaChart Posted - 1 month ago

$MRUS https://anachart.com/wp-content/uploads/ana_temp/1719421318_soc-img.jpg

intratio Posted - 1 month ago

$MRUS Merus N.V. The mathematical model is forecasting that the stock price of this company will not increase any time soon and has a dramatic negative long-term outlook

StockDeals Posted - 1 month ago

$TSLA $WULF $PLNT $MRUS $SMR 06/25 Watchlist https://youtu.be/v21FAsOsvr0?si=FBnm_vi2W9Rm7Nw_

Doozio Posted - 1 month ago

$MRUS explosive 🧠👀 in 🧠⏰

DesiMiami Posted - 1 month ago

$MRUS

net0trader Posted - 1 month ago

@MaverikIT @DonCorleone77 @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @IsabellaDC @CycleTrade @bearcharts $MRUS here another biotech that looks peachy…. Worth a place in watchlist.

intratio Posted - 1 month ago

$MRUS https://www.intratio.com/stock-forecast/MRUS Merus N.V. Our engine is making the inference this company s value will shortly go down and will continue to have a very poor trend over the next months

intratio Posted - 1 month ago

$MRUS https://www.intratio.com/stock-forecast/MRUS The model lets us believe the price action of this stock will lose ground in the coming days and will suffer a highly negative trend that will persist

mostbullish Posted - 1 month ago

@Bionoobbb $pdsb $hook $mrus Certainly the most mature, meaning that the others are catching up. All those sensored events on the OS curve might become $pdsb's achilles heel.

intratio Posted - 1 month ago

$MRUS https://www.intratio.com/stock-forecast/MRUS Merus N.V. Our predictive algorithm has detected this stock s value has a negative short-term outlook also clearly lacks long-term fundamentals

Stock_Titan Posted - 1 month ago

$MRUS Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting https://www.stocktitan.net/news/MRUS/merus-mcla-129-demonstrates-promising-single-agent-efficiency-in-me-trluzi6sod2i.html

DonCorleone77 Posted - 1 month ago

$MRUS Merus presents interim data on MCLA-145 monotherapy, combo with pembrolizumab Merus announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology Annual Meeting taking place in Chicago May 31-June 4, 2024. MCLA-145: Solid Tumors - Interim data included in the presentation describe data from patients with advanced/metastatic solid tumors who received MCLA-145 Q2W in 28 day cycles or every three weeks in 21 day cycles. Patients treated with the combination of MCLA-145 and pembrolizumab had cancers that either relapsed after PD-(L)1 therapies or were immunotherapy naive. Rapid oral presentation title: Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab. Observations in the presentation include: As of a January 3, 2024 data cutoff date, 72 pts with multiple cancer types were treated; 25% of pts had non-small cell lung cancer; All patients were heavily pre-treated with a median of 3 prior therapies; prior IO in 49% of the monotherapy pts and 100% of the combination pts; In monotherapy, 52 pts with a variety of tumor types and treated at different dose levels were evaluable for response; 5 partial responses were observed at different dose levels in glioblastoma, sarcoma, cervical, anal, and gastric cancer by Response Evaluation Criteria in Solid Tumors v1.1. per investigator assessment; 2 of 6 pts PRs were observed for pts treated at the recommended dose for expansion, 40 mg Q3W; 3 of 6 PRs were observed for pts with evaluable baseline tumor CD8 T-cell density of greater than or equal to 250 cells/mm2 responded; In combination with pembrolizumab, 19 pts with a variety of tumor types and treated at different dose levels were evaluable for response; 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W; 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W; 3 pts were continuing combination therapy at cutoff date; MCLA-145 monotherapy or in combination with pembrolizumab had a well-tolerated and manageable safety profile at the RDE, 40mg Q3W; Shifting from Q2W to Q3W resulted in a 50% reduction of Grade greater than or equal to3 treatment-emergent adverse events in both monotherapy and combination therapy; Liver toxicity, a common CD137 related adverse event, was controlled with no G4 events observed at Q3W.

Stock_Titan Posted - 1 month ago

$MRUS Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting https://www.stocktitan.net/news/MRUS/merus-presents-interim-data-on-mcla-145-monotherapy-and-in-ue05hq24bcbv.html

intratio Posted - 1 month ago

https://www.intratio.com/stock-forecast/MRUS Our network computed that this company s market value will not increase any time soon and is poised to drop further in the coming weeks $MRUS

intratio Posted - 1 month ago

https://www.intratio.com/stock-forecast/MRUS Merus N.V. The automated equity analyst deduces that this stock s value has bleak prospects for the foreseeable future and foretells a grimly dismal future $MRUS

RPOC1234 Posted - 05/30/24

@mikeywo well said. Just wait until $MRUS presents on 6/3. Gonna get U-G-L-Y

Capitulation_0 Posted - 05/30/24

$INSM This and $MRUS.. big winners

GTM86 Posted - 05/30/24

$MRUS you have to love these institutional scams. Would love to short it, but you know how these go.

greenype Posted - 05/30/24

lots of bios raising money $CYTK $VKTX $MRUS $INSM

RPOC1234 Posted - 05/30/24

@Ontherag only the beginning. $MRUS does a nice raise and presents on 6/3. No end in sight for $PDSB

RPOC1234 Posted - 05/30/24

@Bilosellhigher @Rangudoc Nice raise by $MRUS.